Alnylam's Record Quarter Meets Brutal Market Math
Published on 08/02/2026 at 17:52 | Redaktion boerse-global.de
The gap between corporate fundamentals and share-price reality rarely yawns as wide as it does at Alnylam right now. The RNAi therapeutics specialist just posted its first-ever billion-dollar quarter for its flagship heart drug Amvuttra — and investors responded by dumping the stock with remarkable aggression.
By Friday's close, the shares had settled at €177.30, a 25.78% collapse over just seven trading sessions. That leaves the equity barely 3% above its 52-week low of €172.15, with the year-to-date decline stretching to roughly 48%.
The Numbers That Should Have Been Enough
The second-quarter print, delivered on July 30, showed total revenue of $1.172 billion — a 74% year-over-year surge. On its face, that is the kind of figure that usually sends biotech stocks soaring. Instead, the market fixated on what came attached to it: a downward revision to the 2026 outlook for the TTR franchise.
Management now guides for $4.2 billion to $4.5 billion in TTR-related revenue next year, trimmed from the previous range of $4.4 billion to $4.7 billion. The explanation centers on a normalization effect. The initial surge following the 2025 label expansion into ATTR-CM — the heart condition that represents the therapy's biggest opportunity — was fueled by pent-up demand from already-diagnosed patients. That second-line pool has now largely been worked through, and the question hanging over the stock is whether first-line patient flow can fill the gap.
Should investors sell immediately? Or is it worth buying Alnylam?
A Market Split Down the Middle
The bulls and bears are drawing sharply different conclusions from the same set of facts.
For the optimists, the competitive landscape has rarely looked more favorable. Reports indicate that Wainua, the AstraZeneca and Ionis collaboration, failed its pivotal CARDIO-TTRansform study in ATTR-CM. That leaves Amvuttra as the only RNAi-based option in the segment — a quasi-monopoly position that could compound over time. The pipeline adds further support: the FDA has accepted the Cemdisiran application, developed with Regeneron, under Priority Review, with a decision expected in November 2026.
The technical picture also suggests the sell-off may have run too far. The 14-day RSI has fallen to 23.0, deep in oversold territory that historically precedes at least a temporary stabilization. Analysts see substantial upside from here, with the average price target sitting at €374.50 — more than double the current quote. Even JPMorgan and Needham, which trimmed their targets after the guidance cut, maintained positive ratings.
The bears counter with chart evidence that is hard to dismiss. Alnylam trades 42.30% below its 200-day moving average of €307.26, a configuration that typically signals a sustained downtrend rather than a dip within an uptrend. The 2026 performance of minus 47.68% reflects genuine investor skepticism about the company's intermediate-term growth trajectory.
Perhaps more troubling for the bull case: the guidance cut arrived even as the primary competitor stumbled. That suggests the slowdown is internally driven — potentially pricing pressure or the pace of ATTR-CM diagnosis rates — rather than a function of intensifying competition. Meanwhile, the company's aggressive expansion into areas like Alzheimer's with Mivelsiran and AI-enabled development platforms consumes capital and weighs on margins precisely when the core TTR business is losing momentum.
The Technical Crossroads
The coming week shapes up as a decisive test. The €172.15 level represents the last line of defense; a break below it could trigger further institutional selling and extend the capitulation that began with the earnings release. Holding it, however, could set the stage for a bounce toward the 50-day average of €250.99 — though traders would be wise to treat such a move as a classic dead-cat rebound rather than evidence of a fundamental turnaround.
Alnylam at a turning point? This analysis reveals what investors need to know now.
Volatility remains a defining feature of this stock, with annualized levels around 91.23%. That cuts both ways: it amplifies downside risk but also means the oversold condition could resolve violently to the upside if sentiment shifts.
The next hard catalyst sits months away — the FDA's Cemdisiran decision in November 2026. Until then, the price action around the 52-week low will serve as the market's primary barometer for whether Alnylam's growth pause is a temporary breather or the beginning of something more structural. The European Society of Cardiology congress later in August could inject additional movement, particularly if competitors present new data.
For now, the fundamental story remains intact on paper. The question is whether the market's shattered confidence can be rebuilt before the share price forces the issue.
Ad
Alnylam Stock: New Analysis - 2 August
Fresh Alnylam information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
